Patient-derived Xenograft Core Facility (PDXCF)

项目概要/摘要 最近建立了患者源性异种移植核心设施（PDXCF）， 在免疫缺陷（NSG）小鼠的繁殖群体中的机构投资，以及癌症研究人员的努力， 致力于开发易于处理的人类肿瘤动物模型的研究者。联合国的使命 PDXCF旨在生成与异质性人类癌症非常相似的尖端癌症模型， 肿瘤微环境（TME）生物医学研究卓越中心（CoBRE）的研究人员作为 最高优先级，并在校园内的调查人员，以扩大这一资源的整体影响。核心将 能够增强对TME的理解，促进新型癌症治疗剂的开发，并改善 临床前药物评价。向研究者提供的服务将根据研究需要量身定制 TME CoBRE中的项目。PDXCF核心将提供以下服务：1）组织移植 研究者提供的用于生产新PDX系的样品; 2）已建立的PDX系的繁殖;以及3） 协助提交IRB和IACUC方案/修正案。通过扩大研究基础设施， 这一核心设施使研究人员能够更有竞争力的校外资金，建立和发展 生产性研究计划，并改善基础科学转化为治疗应用的过程。 该提案描述了设施沿着提供的服务及其管理计划、收费结构， 优先顺序、质量保证计划以及在项目生命周期及以后维持设施的策略。 WVU PDXCF的具体目标是：1）推进翻译研究和最佳生产力， 项目负责人（PL）; 2）支持和开发初始TME CoBRE之外的应用程序的核心 项目负责人，并支持WVUCI和其他WV机构发展奖（IDEA）的活动 共同的总体目标是通过创新的转化减少癌症健康差异的计划 科学重要的是，这一核心设施将增加来自患者群体的肿瘤细胞的可用性， 在目前可用的商业PDX来源中代表性不足。

PROJECT SUMMARY/ABSTRACT The Patient-Derived Xenograft Core Facility (PDXCF) has been recently established and evolved from institutional investments in a breeding colony of immunodeficient (NSG) mice, and the efforts of a cancer research investigator who worked to develop tractable animal models of human tumors. The mission of the PDXCF is to generate cutting edge cancer models that closely resemble heterogeneous human cancers for investigators in the Tumor Microenvironment (TME) Center of Biomedical Research Excellence (CoBRE) as the top priority, and to investigators across the campus to broaden overall impact of this resource. This core will enable enhanced understanding of the TME, facilitate development of novel cancer therapeutics, and improve pre-clinical drug evaluation. Services offered to investigators will be tailored to best fit the needs of research projects in the TME CoBRE. The PDXCF core will provide the following services: 1) transplantation of tissue samples provided by investigators to produce new PDX lines; 2) propagation of established PDX lines; and 3) assistance with submission of IRB and IACUC protocols/amendments. By expanding the research infrastructure, this core facility enables researchers to be more competitive for extramural funding, establish and grow productive research programs, and improve the process of translating basic science to therapeutic application. The proposal describes services provided by the facility along with its management plan, fee structure, prioritization, quality assurance plan, and strategies to sustain the facility over the life of the project and beyond. The Specific Aims of the WVU PDXCF are: 1) to advance the translational research and optimal productivity of the Project Leaders (PLs); 2) to support and develop the core for applications outside the initial TME CoBRE project leaders, and to support the activities of the WVUCI and other WV Institutional Development Award (IDeA) programs that share the overarching goal to reduce cancer health disparities through innovative translational science. Importantly, this core facility will increase the availability of tumor cells from a patient population that is underrepresented in currently available commercial PDX sources.